Fasenra

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Benralizumab
Indications/Uses
Add-on maintenance treatment in adults w/ severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Dosage/Direction for Use
SC 30 mg every 4 wk for the 1st 3 doses, then every 8 wk thereafter.
Contraindications
Special Precautions
Hypersensitivity reactions (eg, urticaria, papular urticaria, rash) following administration. Do not inj into areas w/ tender, bruised, erythematous, or hardened skin. Should not be used to treat acute asthma exacerbations; seek medical advice if asthma remains uncontrolled or worsens after treatment initiation. Not recommended to abruptly discontinue corticosteroids after initiation of Fasenra therapy. Patients w/ pre-existing helminth infections. Avoid use during pregnancy. Lactation. Childn 5-18 yr.
Adverse Reactions
Pharyngitis; hypersensitivity reactions; headache; pyrexia, inj site reaction.
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Fasenra soln for inj 30 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in